Breaking News Instant updates and real-time market news.

PCRX

Pacira

$29.50

0.65 (2.25%)

14:27
04/06/18
04/06
14:27
04/06/18
14:27

Pacira pares gains after link pulled from FDA page for Exparel

A rise in shares of Pacira earlier in the session had been attributed to an FDA webpage that briefly included a link to a label for Exparel. That link, however, did not work. Subsequently, that link has been pulled from the NDA 022496 page for Pacira. The Fly notes that today was the FDA's PDUFA date for potential expansion of Exparel's label to specify nerve block. Shares of Pacira are off earlier highs, but remain up about 9.5% at $32.28 as of time of writing. Reference Link

  • 06

    Apr

  • 16

    Apr

PCRX Pacira
$29.50

0.65 (2.25%)

04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.
03/21/18
JEFF
03/21/18
NO CHANGE
Target $49
JEFF
Buy
Pacira shares could be positioned for rebound, says Jefferies
Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.
03/20/18
GHSC
03/20/18
NO CHANGE
Target $42
GHSC
Buy
Pacira price target lowered to $42 after Heron data at Seaport Global
Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.
03/19/18
JEFF
03/19/18
NO CHANGE
Target $30
JEFF
Buy
Heron pain drug 'hits a home run' in Phase III studies, says Jefferies
Jefferies analyst Biren Amin says Heron Therapeutics's (HRTX) HTX-011 "hits a home run" by meeting all primary and key secondary endpoints this morning from Phase III trials in bunionectomy and hernia repair. Safety looked clean in both studies, and HTX-011 produced durable pain reduction up to 72 hours and significant opioid sparing effect and differentiates from generic bupivacaine, Amin tells investors in a research note. The analyst believes HTX-011 should receive a superiority claim versus generic bupivacaine in its label for both bunionectomy and hernia surgery. Amin notes that Pacira's (PCRX) Exparel does not have this claim in its label. He assumes peak sales of $545M for HTX-011 and keeps a Buy rating on Heron with $30 price target.

TODAY'S FREE FLY STORIES

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:55
08/14/18
08/14
16:55
08/14/18
16:55
Hot Stocks
LRAD Corporation says 'well positioned to achieve record fiscal year revenues' »

"LRAD is in a much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:54
08/14/18
08/14
16:54
08/14/18
16:54
Hot Stocks
Breaking Hot Stocks news story on LRAD Corporation »

LRAD Corporation reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:53
08/14/18
08/14
16:53
08/14/18
16:53
Earnings
LRAD Corporation reports Q3 EPS 0c, one estimate 0c »

Reports Q3 revenue $7.5M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

CDNA

CareDx

$16.87

-0.13 (-0.76%)

16:50
08/14/18
08/14
16:50
08/14/18
16:50
Hot Stocks
CareDx CFO Michael Brian Bell sells 12,500 shares of company stock »

CareDx CFO Michael Brian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

VNDA

Vanda Pharmaceuticals

$21.60

0.15 (0.70%)

16:46
08/14/18
08/14
16:46
08/14/18
16:46
Hot Stocks
Vanda Pharmaceuticals wins denial of petition for rehearing on Fanapt »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$193.08

-1.03 (-0.53%)

16:45
08/14/18
08/14
16:45
08/14/18
16:45
Recommendations
Home Depot analyst commentary  »

Home Depot underlying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FANG

Diamondback Energy

$133.75

1.84 (1.39%)

16:45
08/14/18
08/14
16:45
08/14/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Diamondback Energy »

Diamondback Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$98.41

1.32 (1.36%)

, UTX

United Technologies

$132.40

0.23 (0.17%)

16:42
08/14/18
08/14
16:42
08/14/18
16:42
Hot Stocks
Pershing Square adds Lowe's, cuts stake in ADP »

Bill Ackman's…

LOW

Lowe's

$98.41

1.32 (1.36%)

UTX

United Technologies

$132.40

0.23 (0.17%)

MDLZ

Mondelez

$41.87

-0.03 (-0.07%)

ADP

ADP

$141.17

1.48 (1.06%)

QSR

Restaurant Brands

$62.20

0.355 (0.57%)

CMG

Chipotle

$493.33

8.97 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 22

    Aug

  • 07

    Sep

  • 11

    Sep

  • 12

    Sep

  • 24

    Sep

DXC

DXC Technology

$86.56

2.02 (2.39%)

16:41
08/14/18
08/14
16:41
08/14/18
16:41
Hot Stocks
DXC Technology awarded $400M contract by Wisconsin DHS »

The Wisconsin Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

16:39
08/14/18
08/14
16:39
08/14/18
16:39
General news
API crude inventories for week of August 10 »

API reports that crude…

CSOD

Cornerstone OnDemand

$52.59

0.48 (0.92%)

16:35
08/14/18
08/14
16:35
08/14/18
16:35
Recommendations
Cornerstone OnDemand analyst commentary  »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 04

    Sep

  • 06

    Sep

  • 07

    Sep

  • 12

    Sep

  • 12

    Sep

ATNM

Actinium Pharmaceuticals

$0.62

0.003 (0.49%)

16:34
08/14/18
08/14
16:34
08/14/18
16:34
Conference/Events
Actinium Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 04

    Sep

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

16:34
08/14/18
08/14
16:34
08/14/18
16:34
Earnings
Perspecta sees FY18 pro forma revenue $4.150B-$4.250B, consensus $4.2B »

Sees FY19 adjusted EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FCN

FTI Consulting

$80.32

0.33 (0.41%)

16:33
08/14/18
08/14
16:33
08/14/18
16:33
Syndicate
Breaking Syndicate news story on FTI Consulting »

FTI Consulting files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

16:32
08/14/18
08/14
16:32
08/14/18
16:32
Hot Stocks
Perspecta reports Q1 adjusted EPS 54c, consensus 46c »

Reports Q1 revenue $793M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

SBBP

Strongbridge Biopharma

$6.25

0.3 (5.04%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Syndicate
Strongbridge Biopharma files to sell 9M ordinary shares »

Cowen and Stifel are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HWC

Hancock Whitney

$51.40

0.6 (1.18%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Hancock Whitney names Christopher Ziluca as new Chief Credit Officer »

Hancock Whitney has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRI

Atrion

$656.00

9 (1.39%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Atrion increases quarterly cash dividend by 13% »

Atrion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIK

Tel-Instrument

$2.60

(0.00%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Tel-Instrument receives NYSE non-compliance letter »

Tel Instrument…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/14/18
08/14
16:30
08/14/18
16:30
Options
Preliminary option volume of 16.1M today »

Preliminary option volume…

DLPN

Dolphin Entertainment

$2.96

(0.00%)

16:29
08/14/18
08/14
16:29
08/14/18
16:29
Earnings
Dolphin Entertainment reports Q2 EPS (1c), consensus 2c »

Reports Q2 revenue $5.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

BK

BNY Mellon

$50.97

0.825 (1.65%)

, GE

General Electric

$12.35

-0.09 (-0.72%)

16:29
08/14/18
08/14
16:29
08/14/18
16:29
Hot Stocks
Trian Fund boosts BNY Mellon, lowers stake in Wendy's »

Nelson Peltz's Trian…

BK

BNY Mellon

$50.97

0.825 (1.65%)

GE

General Electric

$12.35

-0.09 (-0.72%)

MDLZ

Mondelez

$41.87

-0.03 (-0.07%)

WEN

Wendy's

$17.84

0.48 (2.77%)

SYY

Sysco

$74.19

1.47 (2.02%)

PG

Procter & Gamble

$81.31

-0.21 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 07

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

16:28
08/14/18
08/14
16:28
08/14/18
16:28
Syndicate
ViewRay files to sell $125M of common stock »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

LMB

Limbach Holding

$10.70

0.11 (1.04%)

16:26
08/14/18
08/14
16:26
08/14/18
16:26
Earnings
Limbach Holding raises FY18 revenue view to $530-$550M from $520M-$540M »

Consensus $527.77M. Now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

MRSN

Mersana Therapeutics

$12.75

0.04 (0.31%)

16:26
08/14/18
08/14
16:26
08/14/18
16:26
Earnings
Mersana Therapeutics reports Q2 EPS (54c), consensus (58c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 15

    Aug

  • 04

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.